AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US

Click here to view online. Add this email to your safelist.

7 October 2016

AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.